Cutaneous T-cell lymphoma

Prescribing Notes:

• The position of specialist treatment in this specialist dermatology pathway is not intended to guide on place in therapy. The place in therapy is directed by a dermatology specialist prescriber experienced in the management of the condition, use is in line with relevant local or national guidance.
• Refer to specialist guidelines for the management of Mycosis fungoides-type T-cell lymphoma.
• The patient information leaflet on Mycosis fungoides-type T-cell lymphoma from the British Association of Dermatologists provides an overview of available treatment options.
• Most patients are managed with ‘skin directed therapy (SDT)’ there are a number of options used by specialists including steroid creams and phototherapy.
• Ledaga is approved for use in line with national guidance for the Topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.
• SMC recommendation - bexarotene (Targretin) is recommended for use in Scotland as a second line treatment for patients with advanced (stages IIb or III) cutaneous T-cell lymphoma. Bexarotene treatment should normally be initiated and supervised by haematologists, dermatologists or oncologists and used for patients who have proved refractory both to local skin directed therapy and to at least one systemic treatment.